InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
0
T+90 hit rate
63%
T+90 mean return
-1.8%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Katkin Keith, Director. Officer active across 5 companies, notably RIGEL PHARMACEUTICALS INC. Cumulatively, 14 reports have been recorded. Split: 1 buy · 0 sell. Total volume traded: €81k. Activity tracked since 19 May 2021. The latest transaction was filed on 19 May 2025 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations14 total
10,000 shares@ US$9.11229.8% of flowCommon StockSEC:0000950170-25-074289:0
Ideal exit: 13 Feb 2026 (T+270)
34,403 shares0Common StockSEC:0001367644-25-000106:0
25,000 shares0Common StockSEC:0000950170-25-016363:0
17,430 shares0Common StockSEC:0001367644-24-000089:0
17,000 shares0Common StockSEC:0001562180-24-001218:0
33,847 shares0Common StockSEC:0001367644-23-000105:0
16,000 shares0Common StockSEC:0001562180-23-000943:0
20,782 shares@ US$7.8861.6% of flowCommon StockSEC:0001562180-22-007125:0
2,914 shares@ US$7.888.6% of flowCommon StockSEC:0001562180-22-007011:0
8,595 shares0Common StockSEC:0001367644-22-000061:0
16,000 shares0Common StockSEC:0001562180-22-001074:0
16,000 shares0Common StockSEC:0001562180-22-001074
25,000 shares0Common StockSEC:0001179110-21-005767
25,000 shares0Common StockSEC:0001179110-21-005767:0
14 of 14 declarations
About Katkin Keith
Keith Katkin serves as a Director for RIGEL PHARMACEUTICALS INC and Syndax Pharmaceuticals Inc. In these roles, he contributes to corporate governance and strategic decision-making. His expertise in the pharmaceutical sector allows him to make significant contributions to the leadership of these companies.
